Literature DB >> 11880448

Results of human papillomavirus DNA testing with the hybrid capture 2 assay are reproducible.

Philip E Castle1, Attila T Lorincz, Iwona Mielzynska-Lohnas, David R Scott, Andrew G Glass, Mark E Sherman, John E Schussler, Mark Schiffman.   

Abstract

Reproducibility of the Hybrid Capture 2 Test (HC 2) for human papillomavirus (HPV) DNA detection was evaluated by assaying frozen cervical specimens in 1997 and again in 2001 from 1,775 women with normal cervical cytology. Using a cutoff point of 1.0 pg of HPV DNA/ml between a negative and a positive test result, the result of the kappa test for agreement was 0.72 (a kappa value of >0.60 is considered good agreement). Using cutoff points of 1.0 and 10.0 pg/ml between negative and low positive and between low positive and high positive, respectively, the kappa was 0.68 and the linear-weighted kappa was 0.76. The results of this study indicate that HC 2 testing is reproducible even among cytologically normal women with low test values.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11880448      PMCID: PMC120262          DOI: 10.1128/JCM.40.3.1088-1090.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  10 in total

1.  Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study.

Authors:  M H Stoler; M Schiffman
Journal:  JAMA       Date:  2001-03-21       Impact factor: 56.272

2.  Comparison between hybrid capture II and polymerase chain reaction results among women at low risk for cervical cancer.

Authors: 
Journal:  Ann Epidemiol       Date:  2000-10-01       Impact factor: 3.797

Review 3.  Human papillomavirus and cancer: the epidemiological evidence.

Authors:  N Muñoz
Journal:  J Clin Virol       Date:  2000-10       Impact factor: 3.168

4.  HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica.

Authors:  M Schiffman; R Herrero; A Hildesheim; M E Sherman; M Bratti; S Wacholder; M Alfaro; M Hutchinson; J Morales; M D Greenberg; A T Lorincz
Journal:  JAMA       Date:  2000-01-05       Impact factor: 56.272

5.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.

Authors:  J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz
Journal:  J Pathol       Date:  1999-09       Impact factor: 7.996

6.  Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions.

Authors:  K L Liaw; A G Glass; M M Manos; C E Greer; D R Scott; M Sherman; R D Burk; R J Kurman; S Wacholder; B B Rush; D M Cadell; P Lawler; D Tabor; M Schiffman
Journal:  J Natl Cancer Inst       Date:  1999-06-02       Impact factor: 13.506

7.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

8.  Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial.

Authors:  D Solomon; M Schiffman; R Tarone
Journal:  J Natl Cancer Inst       Date:  2001-02-21       Impact factor: 13.506

9.  Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia.

Authors:  M H Schiffman; H M Bauer; R N Hoover; A G Glass; D M Cadell; B B Rush; D R Scott; M E Sherman; R J Kurman; S Wacholder
Journal:  J Natl Cancer Inst       Date:  1993-06-16       Impact factor: 13.506

10.  Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group.

Authors:  F X Bosch; M M Manos; N Muñoz; M Sherman; A M Jansen; J Peto; M H Schiffman; V Moreno; R Kurman; K V Shah
Journal:  J Natl Cancer Inst       Date:  1995-06-07       Impact factor: 13.506

  10 in total
  20 in total

1.  Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples.

Authors:  Maria T Sandri; Paola Lentati; Elvira Benini; Patrizia Dell'Orto; Laura Zorzino; Francesca M Carozzi; Patrick Maisonneuve; Rita Passerini; Michela Salvatici; Chiara Casadio; Sara Boveri; Mario Sideri
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

2.  The road ahead for cervical cancer prevention and control.

Authors:  J E Tota; A V Ramana-Kumar; Z El-Khatib; E L Franco
Journal:  Curr Oncol       Date:  2014-04       Impact factor: 3.677

3.  Cervical cancer screening intervals and management for women living with HIV: a risk benchmarking approach.

Authors:  Hilary A Robbins; Howard D Strickler; L Stewart Massad; Christopher B Pierce; Teresa M Darragh; Howard Minkoff; Marla J Keller; Margaret Fischl; Joel Palefsky; Lisa Flowers; Lisa Rahangdale; Joel Milam; Sadeep Shrestha; Christine Colie; Gypsyamber DʼSouza
Journal:  AIDS       Date:  2017-04-24       Impact factor: 4.177

4.  Hybrid capture vs. PCR screening of cervical human papilloma virus infections. Cytological and histological associations in 1270 women.

Authors:  Sotirios Tsiodras; John Georgoulakis; Aikaterini Chranioti; Zanis Voulgaris; Amanda Psyrri; Angeliki Tsivilika; John Panayiotides; Petros Karakitsos
Journal:  BMC Cancer       Date:  2010-02-22       Impact factor: 4.430

5.  Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results.

Authors:  Matthew P Stevens; Suzanne M Garland; Elice Rudland; Jeffrey Tan; Michael A Quinn; Sepehr N Tabrizi
Journal:  J Clin Microbiol       Date:  2007-05-09       Impact factor: 5.948

6.  Human papillomavirus genotype specificity of hybrid capture 2.

Authors:  Philip E Castle; Diane Solomon; Cosette M Wheeler; Patti E Gravitt; Sholom Wacholder; Mark Schiffman
Journal:  J Clin Microbiol       Date:  2008-06-25       Impact factor: 5.948

7.  A comparison of linear array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study.

Authors:  Patti E Gravitt; Mark Schiffman; Diane Solomon; Cosette M Wheeler; Philip E Castle
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-05       Impact factor: 4.254

8.  Does pretreatment HPV viral load correlate with prognosis in patients with early stage cervical carcinoma?

Authors:  Yong Mi Kim; Jin Young Park; Kyung Mi Lee; Tae-Wook Kong; Seung-Chul Yoo; Woo Young Kim; Jong-Hyuck Yoon; Suk-Joon Chang; Ki-Hong Chang; Hee-Sug Ryu
Journal:  J Gynecol Oncol       Date:  2008-06-20       Impact factor: 4.401

9.  Papanicolaou tests and molecular analyses using new fluid-based specimen collection technology in 3000 Japanese women.

Authors:  N Masumoto; T Fujii; M Ishikawa; M Mukai; M Saito; T Iwata; T Fukuchi; K Kubushiro; K Tsukazaki; S Nozawa
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

10.  Comparison of the novel human papillomavirus 4 auto-capillary electrophoresis test with the hybrid capture 2 assay and with the PCR HPV typing set test in the detection of high-risk HPV including HPV 16 and 18 genotypes in cervical specimens.

Authors:  Jin Hwa Hong; Seung Hun Song; Jong Kee Kim; Jeong Hyun Han; Jae Kwan Lee
Journal:  J Korean Med Sci       Date:  2009-07-29       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.